Immune thrombocytopenia (ITP) with corticosteroids: “Evaluation of Response”
DOI:
https://doi.org/10.61581/MJSP.VOL04/02/15Keywords:
Initial Response, Complete Response, Immune ThrombocytopeniaAbstract
Objective: to evaluate the response of corticosteroids in newly persistent ITP patients.
Methodology: Descriptive Case series conducted from 30th October 20202 to 29th April 2021 at Armed Forces Bone Marrow Transplant Centre Rawalpindi. A total of 74 individuals with ITP who were both males and females of various ages. Prednisolone was administered orally to patients in maximal dose of 1mg/kg. The initial reaction of platelets count was assessed on day 5 and subsequently every two weeks until the full response was attained. An informed consent was obtained.
Results: Age was 32.0±19.1 years on average. Twenty-four (32.4%) of the patients were over the age of 40 while the majority (n=50, 67.6%) of the patients were under the age of 40 years. There were 1:1.1 patients that were male and female with 36 (48.6%) men and 38(51.4%) women. Twenty (27.0%) individuals had persistent ITP compared to 54 (73.0%) patients who had just been diagnosed. 34 (45.9%) patients had an initial response whereas 43 patients (58.1%) showed a full response. The average initial response time was 5.47±2.39 days and 11.79±6.73 days for full response. The frequency of first didn’t differ statistically significantly by patient age, gender or other subgroups.
Conclusion: Regardless of age, gender, or ITP type, steroids were associated with an initial and complete response in a significant majority of patients with immune thrombocytopenia. Keeping in view with their affordability accessibility favors the use of steroids as first line in these patients.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Asghar Ali Kerio, Amina Risalat Risalat, Hafiz Muhammad Nadeem, Nighat Shahbaz, Tariq Khattaak Azam, Qamar Nisa Chaudhry
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.